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Abstract
Phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), a minor component of the plasma membrane, is important in signal
transduction, exocytosis, and ion channel activation. Thus fluorescent probes suitable for monitoring the PI(4,5)P2
distribution in living cells are valuable tools for cell biologists. We report here three experiments that show neomycin labeled
with either fluorescein or coumarin can be used to detect PI(4,5)P2 in model phospholipid membranes. First, addition of
physiological concentrations of PI(4,5)P2 (2%) to lipid vesicles formed from mixtures of phosphatidylcholine (PC) and
phosphatidylserine (PS) enhances the binding of labeled neomycin significantly (40-fold for 5:1 PC/PS vesicles). Second,
physiological concentrations of inositol-1,4,5-trisphosphate (10 WM I(1,4,5)P3) cause little translocation of neomycin from
PC/PS/PI(4,5)P2 membranes to the aqueous phase, whereas the same concentrations of I(1,4,5)P3 cause significant
translocation of the green fluorescent protein/phospholipase C-N pleckstrin homology (GFP-PH) constructs from
membranes (Hirose et al., Science, 284 (1999) 1527). Third, fluorescence microscopy observations confirm that one can
distinguish between PC/PS vesicles containing either 0 or 2% PI(4,5)P2 by exposing a mixture of the vesicles to labeled
neomycin. Thus fluorescently labeled neomycin could complement GFP-PH constructs to investigate the location of
PI(4,5)P2 in cell membranes. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Although phosphatidylinositol-4,5-bisphosphate
(PI(4,5)P2) comprises only about 1% of the phospho-
lipids in a mammalian cell plasma membrane [1,2], it
plays at least ¢ve important roles in cellular pro-
cesses. First, hydrolysis of PI(4,5)P2 by phosphoino-
sitide-speci¢c phospholipase C (PLC) [3] produces
the second messengers inositol-1,4,5-trisphosphate
(I(1,4,5)P3) and diacylglycerol, which release calcium
from intracellular stores and activate protein kinase
C [4^6]. Furthermore, PI(4,5)P2 binds to the pleck-
strin homology (PH) domain of PLC-N with high
(WM) a⁄nity [7,8]. Second, PI-3 kinase phosphory-
lates PI(4,5)P2 to produce phosphatidylinositol-3,4,5-
trisphosphate (PI(3,4,5)P3), a lipid that has been im-
plicated in regulating cell metabolism, proliferation,
and survival [9]. Third, PI(4,5)P2 may play a role in
cytoskeleton rearrangements [10,11]. Fourth, there is
strong evidence that PI(4,5)P2 is required for exocy-
tosis [12^14]. Fifth, PI(4,5)P2 regulates the activity of
ion channels, e.g. KATP channels [15^18], and en-
zymes, e.g. phospholipase D (PLD) [19].
How can PI(4,5)P2 play so many di¡erent roles?
One widely discussed possibility is that localization
of PI(4,5)P2 to di¡erent cellular membranes and lat-
eral domains within a membrane allows segregation
of the di¡erent signaling pathways that depend on
PI(4,5)P2 [14,20]. Biochemical analysis, e.g. mem-
brane fractionation and lipid extraction [2,21^24],
indicate PI(4,5)P2 is localized mainly in the plasma
membrane, nucleus, and synaptic vesicles [12,25,26].
It is important to have probes speci¢c for PI(4,5)P2
that can be observed in living cells using a non-in-
vasive method, such as £uorescence microscopy.
Constructs of the PLC-N PH domain with green
£uorescent protein (GFP) have been used to study
PI(4,5)P2 distribution in living cells [27,28]. Previous
studies showed this PH domain binds speci¢cally,
with WM a⁄nity to PI(4,5)P2 [7,8]. The molecular
basis for the speci¢city is understood. The PLC-N
PH domain is a rigid cage-like structure that does
not undergo a signi¢cant change in conformation
when it binds to the headgroup of PI(4,5)P2 [29].
Fluorescence microscopy studies of the GFP-PH
constructs show that a major pool of PI(4,5)P2 in
quiescent cells is in the plasma membrane [27,28],
in agreement with the results from biochemical anal-
yses and immuno£uorescence studies with PI(4,5)P2-
speci¢c antibodies [30,31]. Activation of PLC (e.g. by
increasing the Ca2 concentration in the cytoplasm
[28] or stimulating the receptor for platelet activating
factor [27]) produces rapid redistribution of the
GFP-PH constructs to the cytosol. This redistribu-
tion of GFP-PH construct is interpreted as re£ecting
a decrease in the PI(4,5)P2 concentration in the plas-
ma membrane. A recent study [32] suggests, however,
that translocation of the GFP-PH constructs to the
cytosol might re£ect an increase in cytosolic
I(1,4,5)P3 rather than a decrease in PI(4,5)P2 in the
plasma membrane. Previous studies [7,8] demon-
strated that the PLC-N PH domain binds 10-fold
more strongly to I(1,4,5)P3 than to PI(4,5)P2, so a
small increase in cytosolic I(1,4,5)P3 could cause a
signi¢cant redistribution of the GFP-PH probe.
Hence, new probes that are speci¢c for PI(4,5)P2
but do not have a higher a⁄nity for I(1,4,5)P3 are
needed to complement the GFP-PLC-N PH con-
structs in studies of the inositol phospholipid role
in cellular functions.
Here we explore whether £uorescently labeled neo-
mycins may be used as probes for PI(4,5)P2 in bio-
logical membranes. We have chosen neomycin be-
cause it is a small molecule that binds strongly to
PI(4,5)P2 [33^35]. Neomycin is an aminoglycoside
antibiotic with six primary amine groups and an
average charge of +4.5 in a solution containing
100 mM KCl, pH 7 [36]1. Fig. 1 shows the chemical
structures of £uorescently labeled neomycins used in
this study. The a⁄nity of neomycin for PI(4,5)P2 in a
PC/PI(4,5)P2 membrane is about 105 M31 [35]. We
made three types of measurements. First, we deter-
mined if addition of a £uorophore to neomycin alters
its interaction with PI(4,5)P2. Second, we tested
whether addition of I(1,4,5)P3 to the mixture of £uo-
rescently labeled neomycin and vesicles displaces
the probe from the membrane. Third, we tested if
the labeled neomycin can be used to distinguish be-
tween phospholipid membranes with or without
1 In our hands small basic peptides that have been claimed to
bind speci¢cally to PI(4,5)P2 (for a review see [14]), such as a
peptide from PLC-N PH domain, show little a⁄nity for
PI(4,5)P2 in direct equilibrium binding measurements [54]. Neo-
mycin is the only small organic molecule that, to our knowledge,
binds with WM a⁄nity to PI(4,5)P2.
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physiological concentrations of PI(4,5)P2, 1^5% total
lipid. We conclude that £uorescently labeled neomy-
cin is a potentially useful probe that could comple-
ment GFP-PH constructs in the study of PI(4,5)P2
distribution in cellular membranes.
2. Materials and methods
2.1. Materials
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidyl-
choline (PC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phatidylserine (PS), 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphatidylglycerol (PG), and lissamine rhod-
amine B-dipalmitoyl-phosphatidylethanolamine (Rh-
PE) were purchased from Avanti Polar Lipids
(Alabaster, AL). Radiolabeled 1,2-di[1-14C]oleoyl-L-
3-phosphatidylcholine ([14C]PC) was purchased from
Amersham (Arlington Heights, IL), £uorescein-5-iso-
thiocyanate (FITC), 7-amino-3-((((succinimidyl)oxy)-
carbonyl)methyl)-4-methylcoumarin-6-sulfonic acid
(AMCA-S), 6-((7-amino-4-methylcoumarin-3-acetyl)-
amino)hexanoic acid, succinimidyl ester (AMCA-X),
and 2-(3-(diphenylhexatrienyl) propanoyl)-1-hexade-
canoyl-sn-glycero-3-phosphocholine (DPH-PC) were
from Molecular Probes (Eugene, OR). PI(4,5)P2 (am-
monium salt) was isolated from bovine brain extract
(Sigma, St. Louis, MO) as described previously [37].
Phosphatidylinositol-3,4-bisphosphate, dipalmitoyl,
PI(3,4)P2 (ammonium salt) was purchased from Ma-
treya (Pleasant Gap, PA). Neomycin trisulfate was
from Sigma. I(1,4,5)P3 was from Calbiochem-Nova-
biochem (San Diego, CA) and Sigma. Our standard
bu¡er solution consists of 100 mM KCl, 1 mM
MOPS, pH 7.
2.2. Fluorescently labeled neomycin
Neomycin was labeled with FITC, AMCA-S, or
AMCA-X as described below. For the labeling with
FITC, neomycin trisulfate (45.4 mg, 0.05 mmol) and
£uorescein isothiocyanate (FITC; 3.75 mg, 0.0083
mmol) were dissolved in 1 ml of 1 N TEAB (triethyl-
ammonium bicarbonate, pH 7.5); the solution was
stirred for 1 h and left unstirred for 36 h at room
temperature. The solution was concentrated in vac-
uum, and the residue was dissolved in 1 ml of water.
Fig. 1. Chemical structures of the £uorescent neomycin compounds used in this study. FITC is £uorescein-5-isothiocyanate, AMCA-S
is 7-amino-3-((((succinimidyl)oxy)carbonyl)methyl)-4-methylcoumarin-6-sulfonic acid, and AMCA-X is 6-((7-amino-4-methylcoumarin-
3-acetyl)amino)hexanoic acid. For each of these compounds, the neomycin can be modi¢ed at either of the two aminomethylene
(^CH2NH2) groups, and the material used is an inseparable mixture of the two isomers.
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Aliquots of the solution (50 Wl each) were puri¢ed by
HPLC on a C18 silica gel reversed-phase column
(0.45U25 cm), with a linear gradient elution of bu¡-
er A (0.06% aq. tri£uoroacetic acid) to bu¡er B (95%
acetonitrile, 5% water, 0.052% tri£uoroacetic acid), a
£ow rate of 1 ml/min, and absorbance monitoring at
494 nm. A single fraction midway through the gra-
dient was collected from each run, and those frac-
tions were combined, concentrated, and lyophilized
to give a yellow powder (5.5 mg, yield 64%). Electron
spray mass spectrometry (ES-MS) gives m/z 1003.63
for the product. Calculated molecular weight is
1004.2. For labeling with AMCA-S, a coumarin de-
rivative, neomycin trisulfate (27 mg, 0.0297 mmol)
and AMCA-S-SE (7-amino-3-(((succinimidyl)oxy-
carbonyl)methyl)-4-methyl-coumarin-6-sulfonic acid,
2.0 mg, 0.050 mmol) were dissolved in 0.2 ml of
0.1 M NaHCO3 (pH 7.55) and the solution was
stirred for 24 h at room temperature. The solution
was concentrated in vacuum, the residue was dis-
solved in 1 ml of water, and aliquots were puri¢ed
by the same HPLC system as above except that de-
tection was at 353 nm. Fractions containing the
product were pooled together and lyophilized as de-
scribed above to give a pale yellow powder (2.5 mg,
yield 55%). ES-MS gives m/z 910.02. Calculated mo-
lecular weight is 910.58. For labeling with AMCA-X,
another coumarin derivative, neomycin trisulfate
(51.1 mg, 0.056 mmol) and AMCA-X-SE 6-(7-ami-
no-4-methylcoumarin-3-acetyl)amino)hexanoic acid,
succinimidyl ester (2.5 mg, 0.0056 mmol) were dis-
solved in 0.2 ml of 1 N TEAB and 0.1 ml of di-
methylformamide (DMF). The solution was stirred
for 5 h and left unstirred for 72 h at room temper-
ature. The solution was processed as described for
AMCA-S-neomycin to give a yellow powder
(2.8 mg, yield 51%). ES-MS gives m/z 943.00. Calcu-
lated molecular weight is 944.04. The chemical struc-
tures of the compounds we used are shown in Fig. 1.
Fluorescently labeled neomycin was dissolved in
water (Millipore ¢ltered and double quartz distilled)
and stored frozen in small aliquots. We determined
the concentration of the probe by measuring the ab-
sorbance of the £uorophores (for £uorescein O=
73 000 M31 cm31, pH 9; for coumarin O= 19 000
M31 cm31, methanol).
The £uorescence intensity of FITC- and coumarin-
labeled neomycin, either in solution or bound to a
membrane, increases linearly over the range of con-
centrations we investigated (10^250 nM neomycin).
Control experiments show £uorescently labeled neo-
mycin (30^200 nM) remains in solution when the
samples are centrifuged for 1 h. at 100 000Ug. This
result is consistent with our assumption that the la-
beled neomycin exists as a monomer in solution.
There is, however, some loss of the probe on the
walls of the centrifuge tube; we minimized the loss
by pre-washing the tubes with unlabeled neomycin
sulfate. For FITC-neomycin it was su⁄cient to pre-
wash tubes with a solution containing the same con-
centration of neomycin that was used in the binding
experiment. When the tubes were pre-washed, the
concentration of labeled neomycin in bu¡er solution
was the same before and after centrifugation, indicat-
ing this treatment prevents signi¢cant adsorption of
the labeled aminoglycoside to the tube. Coumarin-
labeled aminoglycosides adhere more strongly to
the centrifuge tubes; hence we pre-washed the tubes
with a solution containing a 10-fold higher concen-
tration of unlabeled neomycin for experiments with
this probes.
2.3. Vesicle preparation
We measured initial concentration of lipids in
chloroform using a Cahn electrobalance. In some
experiments, trace amounts of [14C]PC were added
to the lipid mixture to determine the ¢nal lipid con-
centration. The concentrations of I(1,4,5)P3 and lipid
in the solution were also con¢rmed by phosphate
analysis [38]. Lipid mixtures were dried on a rotary
evaporator and resuspended in a sucrose bu¡er
(176 mM sucrose, 1 mM MOPS, pH 7) to produce
multilamellar vesicles. Large unilamellar vesicles
(LUVs) were made by extruding multilamellar
vesicles 10 times through a stack of two polycarbon-
ate ¢lters (100 nm pore diameter) after 5 freeze^thaw
cycles [39]. Vesicles with and without PI(4,5)P2
were prepared on the same day from the same stock
of lipid solutions in chloroform. PI(4,5)P2 in a mem-
brane has an e¡ective net charge of 33 in a 100 mM
KCl, pH 7 solution [36]. Thus we replaced 3 PS by
1 PI(4,5)P2 in the PC/PS/PI(4,5)P2 vesicles to keep
the charge density the same as in the PC/PS vesicles.
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All preparations, binding measurements, and micros-
copy observations were made at room temperature,
22^23‡C.
2.4. Equilibrium binding measurements
Equilibrium binding of labeled neomycins was de-
termined using a sucrose-loaded vesicles assay [40].
Brie£y, labeled neomycin was mixed with the su-
crose-loaded vesicles in 100 mM KCl and the mix-
ture was centrifuged (1 h, 100 000Ug) to separate the
vesicles, which form a pellet, from the unbound neo-
mycin. The supernatant was removed carefully and
its FITC £uorescence was measured (the structure of
the labeled neomycin is shown in Fig. 1). In the ex-
periments with FITC-neomycin, the FITC £uores-
cence of the supernatant re£ects how much neomycin
remained unbound. We obtained the same binding
a⁄nity (see Eqs. 1 and 3) using two di¡erent
FITC-neomycin concentrations (100 and 200 nM),
which controls for a number of possible artifacts
(e.g. that FITC-neomycin does not change the vesicle
surface charge density and that it binds as a mono-
mer). We did not use pellet samples to calculate the
binding because FITC-neomycin bound to a mem-
brane gives a 5-fold lower signal than in solution.
This is obviously a disadvantage of using this partic-
ular probe with biological membranes.
Coumarin £uorescence was the same from a la-
beled neomycin either in bu¡er or bound to a mem-
brane for both AMCA-S- and AMCA-X-neomycin
(the structures of the labels are shown in Fig. 1).
Hence £uorescence measurements of both superna-
tant and pellet were used to calculate percent cou-
marin-neomycin bound as discussed in [40]. We ob-
tained the same binding a⁄nity (see Eqs. 1 and 3)
using 35, 70, or 140 nM of AMCA-X-neomycin.
We describe neomycin binding to membranes with
PI(4,5)P2 in two ways. First, we determine a molar
partition coe⁄cient, K ; this calculation does not re-
quire any assumptions about the mechanism(s) in-
volved in the association of the probe with the mem-
brane. Second, we assume that labeled neomycin
forms a 1:1 complex with PI(4,5)P2 and calculate
the apparent speci¢c association constant, KNÿP,
for this complex; this assumption is consistent with
the available data for unlabeled neomycin [35,36,41].
The molar partition coe⁄cient, K, is the ratio of
the molar concentration of the membrane-bound
neomycin, [Nb], to the concentration of lipid acces-
sible to neomycin, [L], and the concentration of neo-
mycin free in the aqueous solution, [Nf ] :
K  NbLNf : 1
The accessible lipid concentration, the concentra-
tion of the lipid comprising the outer lea£et of the
vesicles, equals about one half of the total lipid con-
centration for LUVs. In the limit of low neomycin
concentration (when binding of neomycin does not
change the a⁄nity of the vesicle for the probe), K
equals the reciprocal of the accessible lipid concen-
tration that binds 50% of neomycin (i.e. [Nb] = [Nf ]).
Eq. 2 describes dependence of the percent neomycin
bound on the accessible lipid concentration [L]:
% neomycin bound  100UK L=1 K L: 2
It is obtained from the mass conservation for neo-
mycin and the de¢nition of the molar partition co-
e⁄cient (Eq. 1) with no assumptions about binding
mechanism (for details see [42^44]). Note Eq. 2 is
equivalent to an equation obtained assuming binding
of one neomycin per one phospholipid. The molar
partition coe⁄cient was obtained by ¢tting Eq. 2 to
the data with one unknown parameter, K.
If we assume that binding is due to formation of
the speci¢c 1:1 neomycin:PI(4,5)P2 complex, the ap-
parent association constant, KNÿP, for this complex
is the ratio of the concentration of the neomycin-
PI(4,5)P2 complex, [N^PIP2], to the concentration
of free accessible PI(4,5)P2, [PIP2], and the concen-
tration of neomycin free in aqueous solution, [Nf ] :
KNÿP  Nÿ PIP2PIP2Nf  : 3
2.5. Measurements of the e¡ect of I(1,4,5)P3 addition
on FITC-neomycin binding
We pre-mixed 80, 100, or 160 nM FITC-neomycin
with sucrose-loaded 5:1 PC/PS vesicles with 1^2%
PI(4,5)P2 (several di¡erent lipid concentrations were
used) and allowed the solution to equilibrate for
15 min. We then added di¡erent amounts of
I(1,4,5)P3 to the neomycin-vesicle solution. The sam-
ples were centrifuged (1 h, 100 000Ug), the superna-
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tant was removed, and FITC £uorescence was meas-
ured. Percent FITC-neomycin bound was calculated
as described for standard equilibrium binding experi-
ments.
The association constant of neomycin with
I(1,4,5)P3 is
KNfÿIP3 
Nf ÿ IP3
IP3Nf  ; 4
where [N^IP3] is the concentration of neomycin
bound to I(1,4,5)P3 and [IP3] is the concentration
of I(1,4,5)P3 free in solution. Under our condi-
tions, [N] is much lower than [PIP2]total and
[IP3]total. Thus the free concentrations of PI(4,5)P2
and I(1,4,5)P3 are approximately equal to the corre-
sponding total concentrations: [PIP2]W[PIP2]total
and [IP3]W[IP3]total. Then combining Eqs. 3 and 4,
and the mass conservation law for PI(4,5)P2,
I(1,4,5)P3, and neomycin, we obtain Eq. 5 which de-
scribes the dependence of the fraction of neomycin
bound to PI(4,5)P2, [N^PIP2]/[N], on the concentra-
tion of I(1,4,5)P3 added to the aqueous phase:
Nÿ PIP2
N 
KNÿPPIP2
1 KNÿPPIP2  KNÿIP3IP3: 5
2.6. Preparation of giant vesicles for microscopy
Giant unilamellar vesicles for microscopy studies
were prepared using a gentle hydration method [45].
For each experiment, we prepared two sets of vesicles
with the same surface charge density: one set con-
tained PI(4,5)P2 ; the other set contained a £uores-
cent marker, but no PI(4,5)P2. For example, we pre-
pared 66:28:2 PC/PS/PI(4,5)P2 and 2:1 PC/PS
vesicles, where the latter contained 0.3 mol% DPH-
PC, allowing us to distinguish these vesicles from the
unlabeled vesicles containing PI(4,5)P2 in a mixed
sample. An appropriate lipid mixture in chloroform
was dried in a v-shaped £ask on a rotary evaporator
under vacuum for 30 min to form a thin ¢lm. The
dried ¢lm was prehydrated for 20 min at 45‡C with
water-saturated argon, and 4^6 ml of the bu¡er so-
lution was gently added to the £ask. The sealed £ask
was incubated at 37‡C for 12^24 h, and 100^200 Wl
of the upper part of the solution was harvested and
used for microscopy studies. Vesicles with or without
PI(4,5)P2 were mixed together at approximately the
same concentrations and the ratio was checked by
viewing a slide. After adding labeled neomycin to
the vesicle mixture, we transferred the sample to a
glass slide and added agarose to inhibit vesicle move-
ment. A typical sample contained about 1 mM of
lipid, 0.2^1 WM of neomycin and 0.5% w/v agarose.
(We cannot measure the exact concentration of lipid
on a slide because the solution of giant vesicles is
very heterogeneous.)
We conducted the same experiments using also 5:1
PC/PS giant vesicles with and without 2 mol%
PI(4,5)P2. We labeled the vesicles without PI(4,5)P2
with either DPH-PC or Rh-DPPE. We obtained the
same results using two di¡erent lipid markers. We
also tested AMCA-X-neomycin.
2.7. Imaging
Images were obtained using a ¢xed stage micro-
scope (Axioskop, Zeiss), Plan-NEOFLUOR 63U-
oil objective (Zeiss), and Micro-Max Princeton
CCD camera (Princeton). The £uorescence of FITC
was measured using a short band path ¢lter set 41001
from Chroma: exciter 460 þ 20 nm, beam splitter
505 nm, and emitter 535 þ 25 nm. The £uorescence
of coumarin or DPH was measured using a short
band path ¢lter set 31000 from Chroma: exciter
360 þ 20 nm, beam splitter 400 nm, and emitter
460 þ 25 nm. Filters for rhodamine were from Omega
Optical: exciter 510 þ 13.5 nm, emitter s 560 nm.
3. Results
We studied the binding of neomycin to phospho-
lipid vesicles with and without PI(4,5)P2. Because
neomycin has an average charge of +4.5 in 100
mM KCl, pH 7 [36], it can bind to negatively
charged membranes both via a non-speci¢c electro-
static accumulation in the di¡use double layer (Gibbs
surface excess, for a review see [46]) and by forma-
tion of a speci¢c complex with the acidic lipid
PI(4,5)P2. To distinguish between these two possibil-
ities, we measured the binding of £uorescently la-
beled neomycin to vesicles with the same surface
charge density, but di¡erent concentrations of
PI(4,5)P2.
The cytoplasmic lea£et of the plasma membrane of
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a typical mammalian cell contains 15^30 mol% PS
and 1^2 mol% PI(4,5)P2 [1,21,22,25,47]. Hence we
¢rst tested FITC-neomycin binding to phospholipid
vesicles with 17 mol% (5:1 PC/PS) and 33 mol% (2:1
PC/PS) PS. Then we substituted 6 mol% PS in the
lipid mixture with 2 mol% PI(4,5)P2 to keep the sur-
face charge density constant and measured the bind-
ing of labeled neomycin to these PI(4,5)P2 containing
vesicles.
3.1. PI(4,5)P2 increases the binding of
FITC-neomycin to phospholipid vesicles
Fig. 2A shows binding isotherms for FITC-neo-
mycin and 5:1 PC/PS (squares) or PC/PS/PI(4,5)P2
(circles) vesicles with the same surface charge density.
We ¢rst describe the data in terms of the molar par-
tition coe⁄cient, K, and then interpret the results
assuming formation of a 1:1 neomycin:PI(4,5)P2
complex. The molar partition coe⁄cients are
K = 1.2U102 M31 for 5:1 PC/PS vesicles without
PI(4,5)P2 and K = 4.5U103 M31 for the vesicles
with 2 mol% PI(4,5)P2. Thus addition of PI(4,5)P2
to the lipid mixture increases the binding 40-fold.
Fig. 2B shows binding isotherms for FITC-neomy-
cin and 2:1 PC/PS (squares) or PC/PS/PI(4,5)P2
(circles) vesicles with the same surface charge den-
sity. The molar partition coe⁄cient is 6-fold higher
for the vesicles containing 2 mol% PI(4,5)P2
(K = 2.7U103 M31 for 2:1 PC/PS2 and 1.5U104
M31 for PC/PS/PI(4,5)P2 vesicles).
The results shown in Fig. 2A,B indicate that
FITC-neomycin binds speci¢cally to PI(4,5)P2. If
Fig. 2. PI(4,5)P2 increases FITC-neomycin binding to 5:1 PC/
PS (A) and 2:1 PC/PS (B) vesicles. In both ¢gures the percent
FITC-neomycin (100 nM) bound to vesicles is plotted against
the concentration of the accessible lipid. (A) The vesicles were
made from a 5:1 PC/PS (F) or a PC/PS/PI(4,5)P2 (b) lipid mix-
ture with the same surface charge density and 2 mol%
PI(4,5)P2. Each point is an average of duplicate samples. The
solid curves are the best ¢ts of Eq. 2 to the data with the molar
partition coe⁄cients of K = 1.2U102 M31 and 4.5U103 M31.
Addition of 2% PI(4,5)P2 increases the binding of FITC-neomy-
cin to the 5:1 PC/PS vesicles 40-fold. (B) The vesicles were
made from a 2:1 PC/PS (F) or a PC/PS/PI(4,5)P2 (b) lipid mix-
ture with the same surface charge density and 2 mol%
PI(4,5)P2. Each point is an average of duplicate samples. The
solid curves are the best ¢ts of Eq. 2to the data with the molar
partition coe⁄cients of K = 2.7U103 M31 and 1.5U104 M31.
Addition of 2 mol% PI(4,5)P2 increases the binding of FITC-
neomycin to the 2:1 PC/PS vesicles 6-fold. The experiments in
this ¢gure and Fig. 3 were done using sucrose-loaded vesicles
and our standard bu¡er, 100 mM KCl, 1 mM MOPS, pH 7.
6
2 Binding of FITC-neomycin to PC/PS vesicles depends steeply
on the mole fraction of PS in the membrane, as expected for this
poly-basic compound. Binding of FITC-neomycin increases 25-
fold when the mol% PS is increased 2-fold from 17 to 33 mol%
(Fig. 2).
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we calculate the apparent speci¢c association con-
stant, KNÿP, for a 1:1 neomycin:PI(4,5)P2 complex
from Eq. 3, we obtain KNÿP = 2U105 M31 and
5U105 M31 for vesicles with a surface charge density
equivalent to 17 and 33 mol% PS, respectively. We
also measured FITC-neomycin binding to 98:2 PC/
PI(4,5)P2 vesicles and obtained a molar partition co-
e⁄cient K = 1.5U103 M31 and an apparent speci¢c
association constant KNÿP = 105 M31 (data not
shown). The value of KNÿP is the same as that re-
ported for unlabeled neomycin binding to PC/
PI(4,5)P2 vesicles [35]; thus, attachment of this £uo-
rophore to neomycin does not a¡ect signi¢cantly
neomycin a⁄nity for PI(4,5)P2.
As an aside, we note that KNÿP is only an apparent
binding constant because it depends on the surface
charge density of the vesicles (mol% acidic lipid): for
FITC-neomycin KNÿP equals 105 M31 for PC/
PI(4,5)P2, 2U105 M31 for 5:1 PC/PS+2 mol%
PI(4,5)P2, and 5U105 M31 for 2:1 PC/PS+2 mol%
PI(4,5)P2 vesicles. The KNÿP depends on the surface
charge density of the vesicles (surface potential) be-
cause the concentration of poly-basic neomycin close
to the negatively charged membrane is enhanced by
a non-speci¢c long-range electrostatic attraction
(Boltzmann factor) (see [35,48] for a detailed discus-
sion).
3.2. The molar partition coe⁄cient increases linearly
with mol% PI(4,5)P2 in the membrane
To study how the binding of neomycin depends on
the mol% PI(4,5)P2 in a membrane, we measured
binding of the FITC-labeled neomycin to 2:1 PC/
PS vesicles containing 0, 1, 2, or 4 mol% PI(4,5)P2.
The results are summarized in Table 1. The ¢rst col-
umn gives the composition of the vesicles used. The
second column gives the values of K obtained by
¢tting Eq. 2 to the data from equilibrium binding
experiments (data from Fig. 2B for 0 and 2 mol%
PI(4,5)P2, data not shown for 1 and 4 mol%
PI(4,5)P2). There is a linear relation between the
amount of PI(4,5)P2 in the vesicles and the molar
partition coe⁄cient: increasing the mol% PI(4,5)P2
in membrane 2-fold increases K approximately 2-
fold. The third column gives the apparent speci¢c
association constant, KNÿP, for neomycin and
PI(4,5)P2 calculated from the data using Eq. 3; as
expected for a 1:1 complex, KNÿP is independent of
the mol% PI(4,5)P2 in the membrane.
All our equilibrium binding results are consistent
with the formation of a 1:1 complex between
PI(4,5)P2 and FITC-neomycin, as was suggested by
previous studies using unlabeled neomycin [35,36,41].
3.3. PI(4,5)P2 increases the binding of
coumarin-labeled neomycin to 2:1 PC/PS vesicles
We also tested neomycin labeled with the coumar-
in derivatives AMCA-S and AMCA-X and obtained
qualitatively similar results to those reported above
for FITC-neomycin. Fig. 3 shows AMCA-X binding
isotherms for 2:1 PC/PS vesicles and PC/PS/
PI(4,5)P2 vesicles with the same surface charge den-
sity, with K = 2U104 M31 and 1U105 M31, respec-
tively. Addition of 2 mol% PI(4,5)P2 increases bind-
ing of AMCA-X-labeled neomycin to 2:1 PC/PS
vesicles 5-fold.
AMCA-S-neomycin binds to membranes 5-fold
less strongly (data not shown) and AMCA-X-neo-
mycin almost 10-fold more strongly than FITC-neo-
mycin (compare Figs. 2B and 3). This increase in the
Table 1
The molar partition coe⁄cients and the apparent association constants for the FITC-neomycin binding to 2:1 PC/PS vesicles with
0^4 mol% PI(4,5)P2
Lipid mixture (mol% PI(4,5)P2 in the mixture) Molar partition coe⁄cient, K (M31) Apparent association constant, KNÿP
(M31)
66:34 PC/PS, 0 mol% 2.7U103 NAa
66:31:1 PC/PS/PI(4,5)P2, 1 mol% 9U103 5U105
66:28:2 PC/PS/PI(4,5)P2, 2 mol% 1.5U104 5U105
66:22:4 PC/PS/PI(4,5)P2, 4 mol% 3.4U104 7U105
aNA, not applicable.
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binding of AMCA-X-neomycin to membranes com-
pared to binding of unlabeled neomycin could be due
to a hydrophobic interaction of the £uorophore with
the lipid head group region. The AMCA-X £uoro-
phore has a hydrophobic linker (see Fig. 1) that
could allow both electrostatic interaction of neomy-
cin and hydrophobic interaction of coumarin with
the membrane, increasing the binding.
3.4. FITC-neomycin does not distinguish between
PI(3,4)P2 and PI(4,5)P2
We measured the binding of FITC-neomycin to
2:1 PC/PS vesicles containing 1 mol% phosphatidyl-
inositol-3,4-bisphosphate (PI(3,4)P2) or phosphati-
dylinositol-4,5-bisphosphate (PI(4,5)P2) (data not
shown). The FITC-neomycin binds equally well
to vesicles with either 1 mol% PI(3,4)P2 or with
1 mol% PI(4,5)P2. PI(4,5)P2 is the major bisphos-
phate inositol lipid in mammalian cells and the dis-
tribution of the probe should reveal mainly its loca-
tion in a living cell.
3.5. I(1,4,5)P3 causes only slight translocation of
labeled neomycin from PC/PS/PI(4,5)P2 bilayers
Upon activation of PLC in a cell, it cleaves
PI(4,5)P2 to produce I(1,4,5)P3 that might compete
for a PI(4,5)P2-speci¢c probe. Because I(1,4,5)P3 is
cytosolic, binding of I(1,4,5)P3 to the probe can
cause translocation of the probe into the cytosol
even when the level of PI(4,5)P2 in the membrane
does not change signi¢cantly: this probably occurs
with the GFP-PLC-N PH constructs [32]. We tested
whether addition of I(1,4,5)P3 to the mixture of
FITC-neomycin with 5:1 PC/PS vesicles containing
1^2 mol% PI(4,5)P2 causes translocation of FITC-
neomycin from the membrane into the aqueous so-
lution. In our experiments, the concentration of ac-
cessible PI(4,5)P2 (2^10 WM) is approximately equal
to the concentration of PI(4,5)P2 present in a cell
plasma membrane. Eq. 5 describes how the fraction
of neomycin bound to PI(4,5)P2 depends on the con-
centration of I(1,4,5)P3 added to the aqueous phase.
We can describe our experimental data on depen-
Fig. 4. I(1,4,5)P3 produces little translocation of neomycin from
the 5:1 PC/PS vesicles with 2 mol% PI(4,5)P2. 100 nM FITC-
neomycin was pre-mixed with sucrose loaded 5:1 PC/PS vesicles
with 2 mol% PI(4,5)P2 (300 WM accessible lipid, 6 WM accessi-
ble PI(4,5)P2), then 5, 10, or 20 WM I(1,4,5)P3 was added and
the samples were centrifuged to determine the percent FITC-
neomycin that remained bound to PI(4,5)P2 (b). Results from
two independent experiments are shown. The solid line is a the-
oretical curve obtained from Eq. 5 with KIP3 = 4U104 M31.
Fig. 3. PI(4,5)P2 increases AMCA-X-neomycin binding to 2:1
PC/PS vesicles. AMCA-X-neomycin binding isotherms for 2:1
PC/PS (F) and 66:28:2 PC/PS/PI(4,5)P2 (b) vesicles. The solid
curves are the best ¢ts obtained using Eq. 2 with the molar
partition coe⁄cients K = 2U104 M31 and 1U105 M31, respec-
tively. Addition of 2 mol% PI(4,5)P2 increases the binding of
AMCA-X-neomycin to the 2:1 PC/PS vesicles 5-fold.
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dence of [N-PI(4,5)P2] on the amount of I(1,4,5)P3
added to the aqueous phase with a value for KNÿIP3
similar to the association constant of neomycin to
PI(4,5)P2. Fig. 4 shows a typical result. In the ab-
sence of I(1,4,5)P3, 55% FITC-neomycin bound to
5:1 PC/PS vesicles with 2 mol% PI(4,5)P2 (left
hand data in Fig. 4). Addition of 5, 10, or 20 WM
I(1,4,5)P3 changed the percent FITC-neomycin
bound to the vesicles only slightly. The theoretical
curve obtained from Eq. 5 with KNÿIP3 = 4U104
M31 describes the experimental data adequately.
This value for KNÿIP3 is comparable to, but slightly
less than, the association constant for neomycin
and PI(4,5)P2 in a PC/PI(4,5)P2 membrane, KNÿP =
1U105 M31. For 2:1 PC/PS membranes with 2 mol%
PI(4,5)P2, or membranes with more PI(4,5)P2, we
observed even less translocation of FITC-neomycin
than is shown in Fig. 4 (data not shown), as expected
from Eq. 5 for conditions where KNÿP is higher.
From these data we conclude that 1^10 WM
I(1,4,5)P3 should not cause signi¢cant translocation
of labeled neomycin from the plasma membrane into
the cytoplasm.
3.6. Speci¢c binding of FITC-neomycin to giant
vesicles containing PI(4,5)P2 can be detected
using £uorescence microscopy
We studied the distribution of £uorescently labeled
neomycin on vesicles with and without PI(4,5)P2 in a
mixture of the two types of vesicles using £uores-
cence digital microscopy. Three kinds of images
were taken from the same location on the slide.
Phase contrast images revealed all the vesicles in fo-
cus at this location. DPH £uorescence images re-
C
Fig. 5. Preferential binding of FITC-neomycin to vesicles con-
taining PI(4,5)P2 in a mixture of vesicles can be detected using
£uorescence microscopy. Two samples of 2:1 PC/PS vesicles,
one with and the other without 2 mol% PI(4,5)P2, were pre-
pared separately, then mixed prior to addition of FITC-neomy-
cin (0.5 WM). The vesicles without PI(4,5)P2 contained 0.3
mol% DPH-PC as a marker. Three images were taken from the
same location on the slide. (A) Phase contrast image shows two
large vesicles. (B) DPH-PC £uorescence indicates that the upper
vesicle contains no PI(4,5)P2, but the lower vesicle contains
PI(4,5)P2. (C) The lower vesicle binds FITC-neomycin. Scale
bar: 10 Wm.
BBAMEM 77782 22-2-00
A. Arbuzova et al. / Biochimica et Biophysica Acta 1464 (2000) 35^4844
vealed vesicles prepared without PI(4,5)P2. FITC
£uorescence images revealed vesicles that bound
FITC-neomycin. A typical example of the images
obtained is shown in Fig. 5A^C. The phase contrast
image in Fig. 5A shows two large vesicles: a V20-
Wm vesicle in the center that is slightly out of focus
and a V10 Wm vesicle in the lower right corner. (A
dot adjacent to the upper right corner of the large
vesicle is an artifact.) Fig. 5B shows the image ob-
tained through the ¢lter set for DPH dye: the central
vesicle has DPH £uorescence and is from the prepa-
ration containing no PI(4,5)P2 ; the lower vesicle has
no DPH £uorescence, and thus contains PI(4,5)P2.
Fig. 5C shows the image obtained through the ¢lter
set for FITC dye: the lower vesicle reveals strong
FITC £uorescence. This vesicle contains PI(4,5)P2
and has FITC-neomycin bound to it, whereas there
is almost no binding of FITC-neomycin to the upper
vesicle that contains no PI(4,5)P2. The results shown
here are consistent with the direct binding measure-
ments presented in Fig. 2B.
We also detected FITC-neomycin bound only to
5:1 PC/PS with 2 mol% PI(4,5)P2 vesicles in a mix-
ture with 5:1 PC/PS vesicles with and without
PI(4,5)P2. Preferential binding of AMCA-X-neomy-
cin to giant unilamellar vesicles containing PI(4,5)P2
was observed in £uorescence microscopy experiments
similar to those shown in Fig. 5 using Rh-PE as
a lipid marker for vesicles without PI(4,5)P2 (data
not shown). The results on PI(4,5)P2 distribution
obtained with coumarin-labeled neomycin are
consistent with the results from the direct binding
measurements shown in Fig. 3. We conclude
that £uorescently labeled neomycin can be used to
distinguish between membranes with and without
PI(4,5)P2 using £uorescence microscopy.
4. Discussion
We report three major results. First, incorporating
physiological concentrations of PI(4,5)P2 (e.g. 2%)
into a lipid bilayer increases the binding of £uores-
cently labeled neomycin (Figs. 2 and 3). FITC-la-
beled neomycin binds to PI(4,5)P2-containing mem-
branes to about the same degree as the unlabeled
neomycin [33,35], and our results are consistent
with formation of a 1:1 neomycin:PI(4,5)P2 complex
with an apparent association constant of 105-106
M31 (Table 1). Second, I(1,4,5)P3 causes little trans-
location of FITC-neomycin from membrane to the
aqueous phase under conditions designed to corre-
spond to those in a living cell (Fig. 4). Third, we
can detect the preferential binding of FITC or cou-
marin-labeled neomycin to vesicles containing 2%
PI(4,5)P2 in a mixture of vesicles with and without
PI(4,5)P2 using £uorescence microscopy on giant
phospholipid vesicles (Fig. 5). These three results
suggest that £uorescently labeled neomycin could
be useful as a probe for monitoring PI(4,5)P2 distri-
bution within cells, complementing the use of GFP-
PH constructs recently developed by several groups
[27,28]3
There are two advantages of using neomycin.
First, it is a small molecule and may probe
PI(4,5)P2 on the cell membranes where larger mole-
cules like the GFP-PH constructs could be sterically
inhibited from binding to PI(4,5)P2. Second, physio-
logical concentrations of I(1,4,5)P3 do not displace
neomycin from the membrane (Fig. 4). In contrast,
I(1,4,5)P3 binds avidly to the PLC-N PH domain and
could produce translocation of the GFP-PH con-
structs from the membrane to the cytosol upon
PLC activation; this could lead to erroneous conclu-
sions regarding the PI(4,5)P2 concentration in a
membrane [32]. Thus £uorescently labeled neomycin,
which is not displaced by I(1,4,5)P3 from PI(4,5)P2-
containing membranes, could be used together with
the GFP-PH constructs. A few technical considera-
tions about £uorescently labeled neomycin that
might be useful to cell biologists are discussed in
Appendix A.
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Appendix A
We expect that injection of 6 1 WM neomycin (a
su⁄cient neomycin concentration to detect PI(4,5)P2
using a £uorescence microscope) will not interfere
signi¢cantly with the inositol pathways in a cell. At
this concentration, neomycin should bind less than
5% of the PI(4,5)P2. No cytotoxicity of neomycin
was observed in human endothelial cells if added to
the cells at low concentrations [49]. However, higher
concentrations of neomycin are used routinely to in-
hibit PLC (for example, in [28,50]) and 100 WM to
5 mM of neomycin added to permeabilized cells
perturbs turnover of the inositol phospholipids
[33,51,52]. Therefore one should use low (6 1 WM)
concentrations of the labeled neomycin.
The available evidence suggests that cell mem-
branes are not permeable to neomycin. Fluorescently
labeled neomycin could be either injected into cells or
added to permeabilized cells. It can also be incorpo-
rated into cells using electroporation, a technique
used routinely to transfect cells with DNA or
RNA. We used the electroporation technique to in-
troduce FITC-neomycin into mammalian kidney
cells. Cells treated with electroporation with 0.5, 1,
or 2 WM of FITC-neomycin in the media were highly
£uorescent and had some staining inside the cell.
Di¡use £uorescence from the cytoplasm possibly in-
dicates that neomycin binds to other negatively
charged molecules in a cell : e.g. it is known that
neomycin binds to 16S ribosomal RNA in prokary-
otic cells [53] and could bind to some RNA in eu-
karyotic cells. Thus FITC-neomycin may be less use-
ful for studies in living cells than other £uorescently
labeled neomycins because its £uorescence decreases
when it binds to membranes. Neomycin labeled with
rhodamine B, X-rhodamine isothiocyanate, or other
labels has been used to investigate the uptake of neo-
mycin and PI(4,5)P2 into cells (S. Ozaki, D.B. DeW-
ald, J.C. Shope, J. Chen and G.D. Prestwich, person-
al communication). Labeling of neomycin with a
polarity sensitive £uorophore that gives a higher
£uorescence signal when the probe is bound to a
membrane (e.g. acrylodan) might be advantageous.
Fluorescently labeled neomycin derivatives may be
obtained from one of the authors (G.D.P.) for col-
laborative projects. FITC, Texas Red, BODIPY, tet-
ramethylrhodamine, rhodamine B, rhodamine-X,
and other adducts have been prepared. Many of
these are commercially available from Echelon Re-
search Laboratories, (http://www.echelon-inc.com).
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